Skip to main content
AVTX filings

Corporate insider profile

Christopher Ryan Sullivan Filing Activity

Latest reported as Chief Financial Officer of Avalo Therapeutics, Inc. (AVTX).

Purchase filings
0
Reported companies
1
Net open-market value
-$3,070,550.54
Latest transaction
Aug 18, 2026

Affiliated corporations

Reported company relationships

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Aug 18, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale72,725$19.94$1,450,420
May 7, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale18,606$24.12$448,818
May 6, 2026Avalo Therapeutics, Inc. (AVTX)Chief Financial OfficerSale47,000$20.19$948,723